THP联合COP方案治疗侵袭性非霍奇金淋巴瘤骨髓浸润临床疗效观察

目的观察吡柔比星（THP）联合COP方案治疗侵袭性非霍奇金淋巴瘤（NHL）骨髓浸润的临床疗效。方法回顾性分析2004年1月至2009年1月收治的侵袭性NHL骨髓浸润患者80例，比较COP方案和THP联合COP方案的近期疗效和不良反应。结果COP方案组40例完全缓解12例。THP联合COP方案组40例完全缓解20例，后者显著高于前者（P〈0．05）。THP联合COP方案I、Ⅱ度血液毒性、心脏毒性、胃肠毒性和肝肾毒性发生率与COP方案相当（P〉0．05），均为毒性两种方案均未出现治疗相关死亡。结论THP联合COP方案是治疗初始侵袭性NHL骨髓浸润的高效、安全的方法。

The Clinic Effect of THP Combined with COP in the Treatment of Invasive non-Hodgkin's Lymphoma with Bone Marrow Infiltration

OBJECTIVE To study the clinic effect of THP combined with COP in the treatment of invasive non-Hodgkin＇s lymphoma （NHL） with bone marrow infiltration. METHOD A retrospective analysis from January 2004 to January 2009 for 80 cases aggressive NHL with bone marrow infiltration were treated by TPH combined with COP compared COP programs only, short-term efficacy and adverse reactions were observed. RESULTS The outcome of COP program group of 40 patients in complete remission in 12 cases, THP Joint COP program group 40 cases of complete remission in 20 cases, which was significantly higher than the former （P〈0.05） . The incidence of Ⅰ,Ⅱ degree of blood toxicity, cardiac toxicity, gastrointestinal toxicity and liver kidney toxicity of both groups was simlar （P〉0.05） , there is no treatment-related deaths occur. CONCLUSION THP combined with COP program is the efficient and safe in treatment of aggressive NHL with bone marrow infiltration .